This HTML5 document contains 94 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n9http://dx.doi.org/10.1007/
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q83841350
rdf:type
wikibase:Item
schema:description
artículu científicu espublizáu en mayu de 2006 наукова стаття, опублікована в травні 2006 wetenschappelijk artikel article scientifique publié en 2006 scientific article published on 03 May 2006
p:P577
wds:Q83841350-C6818FE2-AEEA-46CD-BB24-F907C62C2E89
wdt:P577
2006-05-03T00:00:00Z
p:P2860
wds:Q83841350-E8F5F710-BABE-4F3C-9325-AC26AE1EAB6F wds:Q83841350-E88C4A2C-EF22-4D80-84AC-E843EDDC5808 wds:Q83841350-420BDCF2-EB98-44B3-95E9-72ABEBFEB025 wds:Q83841350-469E4D1A-E5E1-4F44-9EC4-13CF425AC91A wds:Q83841350-228E3365-C4C4-4A0D-90CD-FEF0C4BFFA11 wds:Q83841350-302CB2FE-AF1C-454C-A831-8DC9E9F53827 wds:Q83841350-32B9AE66-2D39-4892-BCF5-E141C533A7F7 wds:Q83841350-342F041D-553C-4653-91B6-B7FE521EA7E3 wds:Q83841350-1D0CB043-58DD-4A76-9C1C-15307C208AAF wds:Q83841350-1E100D1F-BA0D-45AA-AAF7-E65A986135C2 wds:Q83841350-0B3B0FED-D146-48A2-A8AF-A38E5F047AFB wds:Q83841350-0DCC4545-6334-4E8C-A8BB-A3277186102C wds:Q83841350-100C0CDE-0D69-437E-B887-F12C749ED2F6 wds:Q83841350-BE7B140B-4934-442B-8950-A59A464269A2 wds:Q83841350-C5461DB4-ED94-44F1-A693-5B3BD1AF8C43 wds:Q83841350-AA04A73F-22EB-4329-8410-01AD9A04F2CF wds:Q83841350-AB2AD231-793E-49CE-94E5-6DB727988245 wds:Q83841350-97E1F231-0B62-4999-BB1F-DA289F58B6C6 wds:Q83841350-9D470762-FF02-4B1B-81F6-0C1867E2F503 wds:Q83841350-A119FDD0-0150-4F83-A05B-1EA2585CC52D wds:Q83841350-A27837FE-48F5-4E77-9F2C-5A7B495A060D wds:Q83841350-6A100F14-C6DB-4435-A8FC-BD2E4825B78D wds:Q83841350-8CCD360E-46EC-48B2-869B-5B815AB0ED8F wds:Q83841350-92AEEDF9-1300-46B2-9414-FE52569DC1E9 wds:Q83841350-9521E581-6444-40E4-854D-CEDA7EA1F027 wds:Q83841350-04DDFB77-F49A-4CA2-A9A4-D55566FF1A24
wdt:P2860
wd:Q74454469 wd:Q34950386 wd:Q40731084 wd:Q46080503 wd:Q34142790 wd:Q34142797 wd:Q28202479 wd:Q33836037 wd:Q51966491 wd:Q30304095 wd:Q53408731 wd:Q56639150 wd:Q74614019 wd:Q35031205 wd:Q53936002 wd:Q43542367 wd:Q41665809 wd:Q41747291 wd:Q24247467 wd:Q44339656 wd:Q37906640 wd:Q73751289 wd:Q46914426 wd:Q44559884 wd:Q34534593 wd:Q34142781
p:P2093
wds:Q83841350-B79B2160-D245-4375-9A51-12ED3CB649BF wds:Q83841350-BA8F46AF-0A84-421A-A32B-B40971EBA6D1 wds:Q83841350-49C150B5-5018-4DA3-B3BD-8E7C72F92FD5 wds:Q83841350-157D1321-F93F-4D72-8A94-BC1525394E81 wds:Q83841350-1F95CBEC-85B0-48E4-83E0-D807C42B31A8 wds:Q83841350-CDFC2A10-69B1-4B03-B3BA-A804E8C2C304
wdt:P2093
Rodney U Anderson James H Barada Scott Serels Scott MacDiarmid Roger P Goldberg Sherron Kell
rdfs:label
Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder
skos:prefLabel
Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder
schema:name
Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder
p:P1476
wds:Q83841350-E4D3CBD2-3A61-49DC-AA26-1E16872752FD
wdt:P1476
Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder
p:P304
wds:Q83841350-E2D9BFDF-EB34-4587-8FA5-4FE0AAD718BF
wdt:P304
502-511
p:P31
wds:Q83841350-FFF248C7-928E-47C4-AAC0-09E0D248D037
wdt:P31
wd:Q13442814
p:P698
wds:Q83841350-44E05569-39FF-4542-AE0C-A1F8D410893C
wdtn:P698
n10:16724169
wdt:P698
16724169
p:P433
wds:Q83841350-F246EAAF-092D-477F-9FED-1C4899D79D55
p:P478
wds:Q83841350-ADA2D83A-7F27-4A9A-A28F-1261F734D3D4
wdt:P433
5
wdt:P478
17
p:P356
wds:Q83841350-1B87F994-01AC-44AC-AC7E-9939294943A9
wdtn:P356
n9:S00192-005-0057-7
wdt:P356
10.1007/S00192-005-0057-7